,45 This has led to promising therapeutic approaches to overcome refractoriness to therapy and relapse in MCL, including the use of noncovalent Bruton tyrosine kinase inhibitors, immunomodulatory agents, bispecific antibodies, and next generation cell-based therapies.3 Here, BTK is linked to mantle cell lymphoma.